Skip to main content

Adenocarcinoma - GEJ clinical trials at UC Cancer
1 research study open to eligible people

  • DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread

    open to eligible people ages 18 years and up

    This study will find out if trastuzumab deruxtecan is safe and works for participants with certain kinds of cancer. They must have HER2-positive gastric or gastro-esophageal junction (GEJ) cancer: - that cannot be removed surgically - that has moved to other parts of the body - that got worse during or after treatment that included trastuzumab The study will enroll about 72 participants at about 25 to 30 sites. Sites will be in North America, Australia, Israel, and the European Union. There might be other countries as well.

    at UCLA

Last updated: